Coherus BioSciences, Inc.
CHRS
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PDā¦ read more
Healthcare
Biotechnology
11 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.36
Price0.00%
$0.00
1Y
Price
Market Cap
$157.642m
Small
Price/Earnings 3y Avg5y Avg
2.5x
Premium
Premium
Financials Overview
Key metrics over the past few years-356.3%
EBITDA Margin-307.1%
Net Profit Margin-400.5%
Free Cash Flow MarginRevenue
$83.568m
-68.7%
1y CAGR-14.3%
3y CAGR-19.6%
5y CAGREarnings
$154.971m
+443.6%
1y CAGR+191.4%
3y CAGR+143.1%
5y CAGREPS
-$1.60
-740.0%
1y CAGR-199.1%
3y CAGR-149.0%
5y CAGRBook Value
$87.774m
$516.519m
Assets$428.745m
Liabilities$40.694m
DebtDebt to Assets
7.9%
-0.2x
Debt to EBITDAFree Cash Flow
-$90.189m
-341.2%
1y CAGR-75.0%
3y CAGR-188.2%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company